4P-Pharma is a clinical stage biotech company focusing on untreated serious diseases.

AbbVie pharmaceuticals combines advanced science with expertise to make strides in drug and treatment discovery, making a remarkable impact on people's lives. Our core R&D areas of interest include immunology, oncology, neuroscience, eye care and aesthetics complemented by additional focus areas such as virology and cystic fibrosis. We discover and develop new drugs in therapeutic areas that we believe will make the most significant impact on the disease and its management.

Biotech offering solutions to support Cell and Gene therapy development, manufacturing and QC.

leading protein recombinant providing company with custom and GMP capabilities

Adbio partners is a VC firm, with an entrepreneurial spirit dedicated to Life Sciences.

Aenitis develops innovative cost-effective acoustic based cell handling bioprocessing systems.

Aenitis develops innovative cost-effective acoustic based cell handling bioprocessing systems for cell sorting, cell washing, confinement and isolation. Aenitis promotes Mitis™, a device for high flow gentle cell handling, met the GMP processing requirement.

Exosomes from microalgae (MEVs) as a universal delivery system for therapeutics and vaccines.

Externalisation de stockage de ressources biologiques à forte criticité à toutes températures

Directrice de Recherche CNRS Univ. Paris Cité Co-founder: Everzom Coordination: DIM BioConvS

Biotechnology pioneer in Onco-Hematology, Inflammation, Cardiology, Nephrology, Metabolism

Cardiovascular diseases

• Heart failure • Cell therapy • Stem cells • Secretome • Extracellular vesicles • Exosomes • Cardiac fibrosis • CAR-T cells • Cell delivery

www.ariis.fr Depuis 2011, l'ARIIS Alliance pour la recherche et l'innovation des industries de santé est une interface entre les entreprises du secteur de la santé et la recherche publique. Notre objectif : Créer un écosystème de recherche et d’innovation propice aux échanges et synergies entre les acteurs publics et privés au niveau national, et présentant une forte visibilité et attractivité internationale Nos missions : - Faciliter la compréhension de l’écosystème de recherche public - Favoriser les collaborations pour répondre aux futurs enjeux d’innovation en santé - Contribuer aux débats publics pour soutenir le développement de politiques favorables à l'innovation. Les Rencontres Internationales de la Recherche RIR, depuis 2009, et maintenant renommées HYBRIDAYS sont une marque de l'ARIIS avec l'INSERM, maintenant organisées en coordination avec nos partenaires France Biotech, Bpi France et le Leem

hybrid molecule with FC fragment and immunodominant peptide

Pharmaceutical Company

Pharmaceutical industry

The Biocon Bristol Myers Squibb Research & Development Center

Pharma Industry focused on Neurology

Innovative solutions to simplify your research: Automated and standardized functional assays to explore cellular immunity,

25+ years of experience in innovation, technology-driven business development, and change management. Passionate about creating value for the end-user and supporting our clients to address patient safety and advanced therapy quality control. In the Industrial Applications Unit at bioMérieux, I support sales, strategic accounts, and marketing teams, worldwide, focusing on the emerging market of QC in Cell and Gene Therapy

Pharma Quality Control propose des solutions pour le control de qualité des produits pharmaceutique

Bpifrance Investissement is a subsidiary of the French Caisse des Dépôts that manages more than €40B and invests in SMEs and mid-tier companies. Bpifrance invests in life science companies at various stage of development (seed, venture, IPO, PIPE) through several funds (Biothérapies Innovantes des Maladies Rares, InnoBio, InnoBio 2, Large Venture). InnoBio and InnoBio 2 investors include more than 10 major pharmaceutical companies (Sanofi, GSK, Roche, Novartis, Pfizer, Lilly, Ipsen, Takeda, Boehringer Ingelheim, Servier and BMS).

Venture Capital Investment

Public bank supporting innovative SMEs

Brenus Pharma is a clinical stage company developing a pioneering proteomic-driven platform to treat resistant solid tumor with first-in-class proteomic-driven cell immunotherapies focused on tumor antigens. We have developed the STC platform (Stimulated Tumor Cells), a technological platform that mimics relapse conditions and allows the education of the patient's immune system to fight the resistance mechanisms of tumor cells. The lead candidate, STC-1010, is targeting colorectal cancer, the second-leading cause of cancer death worldwide and will undergo a Phase Ia/Ib in mid-2024 in EU to assess first efficacy and safety data in Humans.

Development of new generation's immunotherapy with a plateform acting as therapeutic Cancer Vaccine

At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history. We work every day to transform patients’ lives through science. Each day, our employees around the world work together for patients – they are at the center of everything we do. They inspire us. They are the reason we come to work each day. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation. We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms.

Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.

First-In-Class Immune cell therapies to treat aggresive life-threatening diseases

From retinal development to retinal repair: the use of human pluripotent stem cells

• Vision • Retina • Cell therapy • iPS cells • Organoids • Disease modeling • Neurodegeneration

Leti – Health division

- Lipid Nanoparticles - Drug delivery - RNA delivery - Holographic imaging - In situ monitoring - Quality control - Electrochemical (bio)sensors - Mac - AI,suspended micro/nano-channel resonator, Microfluidic, Organ-on-chip - single cell manipulation

Innovations in the field of skin cell therapy

Human skin – Stem cells – Keratinocytes – Fibroblasts – Regeneration – Skin grafting – Cell therapy – Bio-production – Radio-pathologies – Fibrosis

Cell & Gene CDMO

CELLforCURE is a CDMO specializad in cell & gene therapies manufacturing

Cell therapy developer with proprietary stem cell expansion technology, a leading program in acute myocardial infarction at the end of Phase II and a program in ischemic stroke in preclinical stage.

Technologies and IP for making and using RNA for translation in cells for research and therapeutics.

Investment bank specialized in cross-border investment in life science sector

Oncology

Pancreatic cancer Patients cohorts Biomarkers Patients stratification Animal models of cancer Therapeutic resistance First-in-man clinical trial Intracellular single-domain antibodies Oncolytic virus